N Simon Tchekmedyian

Summary

Publications

  1. doi request reprint Disease progression increases the risk of skeletal-related events in patients with bone metastases from castration-resistant prostate cancer, lung cancer, or other solid tumors
    N Simon Tchekmedyian
    Pacific Shores Medical Group, Long Beach, California 90813, USA
    Cancer Invest 28:849-55. 2010
  2. pmc PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours
    Mark J McKeage
    The University of Auckland, Auckland, New Zealand
    BMC Cancer 12:496. 2012
  3. ncbi request reprint Anemia in cancer patients: significance, epidemiology, and current therapy
    N Simon Tchekmedyian
    Pacific Shores Medical Group, Long Beach, California 90813, USA
    Oncology (Williston Park) 16:17-24. 2002
  4. ncbi request reprint The relationship between psychologic distress and cancer-related fatigue
    N Simon Tchekmedyian
    Pacific Shores Medical Group, Long Beach, California 90813, USA
    Cancer 98:198-203. 2003
  5. ncbi request reprint Treating the anorexia/cachexia syndrome
    N Simon Tchekmedyian
    University of California at Los Angeles School of Medicine, USA
    J Support Oncol 4:506-7. 2006
  6. ncbi request reprint Resource utilisation and time commitment associated with correction of anaemia in cancer patients using epoetin alfa
    Kenneth R Meehan
    Bone Marrow Transplant Program, Section of Hematology Oncology, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire 03756, USA
    Clin Drug Investig 26:593-601. 2006
  7. ncbi request reprint Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications
    Vera Hirsh
    McGill University, Montreal, Quebec, Canada
    Clin Lung Cancer 6:170-4. 2004
  8. ncbi request reprint Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial
    Lee S Rosen
    Developmental Therapeutics, Cancer Institute Medical Group, Los Angeles, California 90025, USA
    Cancer 100:2613-21. 2004
  9. ncbi request reprint Darbepoetin alfa administered every 2 weeks alleviates anemia in cancer patients receiving chemotherapy
    John A Glaspy
    UCLA School of Medicine, UCLA Oncology Center, Los Angeles, California, USA
    Oncology (Williston Park) 16:23-9. 2002
  10. ncbi request reprint Psychological outcomes associated with anemia-related fatigue in cancer patients
    Joel D Kallich
    Health Economics and Epidemiology, Amgen, Inc, Thousand Oaks, California 91320 1799, USA
    Oncology (Williston Park) 16:117-24. 2002

Collaborators

Detail Information

Publications12

  1. doi request reprint Disease progression increases the risk of skeletal-related events in patients with bone metastases from castration-resistant prostate cancer, lung cancer, or other solid tumors
    N Simon Tchekmedyian
    Pacific Shores Medical Group, Long Beach, California 90813, USA
    Cancer Invest 28:849-55. 2010
    ..Bone and overall disease progression correlated with increased SRE risk. Overall, cancer progression correlated with increased SRE risks and zoledronic acid was associated with reduced SRE risks versus placebo...
  2. pmc PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours
    Mark J McKeage
    The University of Auckland, Auckland, New Zealand
    BMC Cancer 12:496. 2012
    ..The purpose of this phase Ib clinical trial was to determine the maximum tolerated dose (MTD) of PR-104 a bioreductive pre-prodrug given in combination with gemcitabine or docetaxel in patients with advanced solid tumours...
  3. ncbi request reprint Anemia in cancer patients: significance, epidemiology, and current therapy
    N Simon Tchekmedyian
    Pacific Shores Medical Group, Long Beach, California 90813, USA
    Oncology (Williston Park) 16:17-24. 2002
    ..An understanding of the importance of anemia and newer agents requiring less frequent dosing, such as darbepoetin alfa (Aranesp), may help physicians and patients overcome some of these barriers...
  4. ncbi request reprint The relationship between psychologic distress and cancer-related fatigue
    N Simon Tchekmedyian
    Pacific Shores Medical Group, Long Beach, California 90813, USA
    Cancer 98:198-203. 2003
    ....
  5. ncbi request reprint Treating the anorexia/cachexia syndrome
    N Simon Tchekmedyian
    University of California at Los Angeles School of Medicine, USA
    J Support Oncol 4:506-7. 2006
  6. ncbi request reprint Resource utilisation and time commitment associated with correction of anaemia in cancer patients using epoetin alfa
    Kenneth R Meehan
    Bone Marrow Transplant Program, Section of Hematology Oncology, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire 03756, USA
    Clin Drug Investig 26:593-601. 2006
    ..This study set out to identify the resource use and time commitment associated with treatment of anaemia with erythropoietic therapy, for both haematology/oncology clinics and patients...
  7. ncbi request reprint Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications
    Vera Hirsh
    McGill University, Montreal, Quebec, Canada
    Clin Lung Cancer 6:170-4. 2004
    ..5 months (P = 0.534). This exploratory analysis demonstrates that patients with a history of SREs are at high risk for subsequent SREs, but zoledronic acid reduces skeletal morbidity regardless of SRE history...
  8. ncbi request reprint Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial
    Lee S Rosen
    Developmental Therapeutics, Cancer Institute Medical Group, Los Angeles, California 90025, USA
    Cancer 100:2613-21. 2004
    ..In the current study, they update these results and report the long-term efficacy and safety of 21 months of treatment with zoledronic acid in a randomized, placebo-controlled trial...
  9. ncbi request reprint Darbepoetin alfa administered every 2 weeks alleviates anemia in cancer patients receiving chemotherapy
    John A Glaspy
    UCLA School of Medicine, UCLA Oncology Center, Los Angeles, California, USA
    Oncology (Williston Park) 16:23-9. 2002
    ..A dose increase to 5.0 microg/kg of darbepoetin alfa administered every 2 weeks may be appropriate in patients with an inadequate initial response...
  10. ncbi request reprint Psychological outcomes associated with anemia-related fatigue in cancer patients
    Joel D Kallich
    Health Economics and Epidemiology, Amgen, Inc, Thousand Oaks, California 91320 1799, USA
    Oncology (Williston Park) 16:117-24. 2002
    ....
  11. ncbi request reprint A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer
    Eric J Small
    UCSF Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94115, USA
    Clin Cancer Res 13:1810-5. 2007
    ....
  12. ncbi request reprint Thalidomide and irinotecan-associated diarrhea
    N Simon Tchekmedyian
    Am J Clin Oncol 25:324. 2002